TravelNet Solutions Will Tout New Capabilities at VRMA Conference ORLANDO, Fla., Oct. 22, 2023 /PRNewswire/ — Minnesota-based TravelNet Solutions (TNS),…
Phase 2b SunRISe-1 study results showed sustained, durable complete responses beyond one year with intravesical gemcitabine delivery system MADRID, Oct.…
Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery system Phase…